Crosstalk Between 0-GlcNAcylation and Phosphorylation in Diabetic Cardiomyopathy
Crosstalk Between 0-GlcNAcylation and Phosphorylation in Diabetic Cardiomyopathy
批准号:
8183667
负责人:
GERALD Warren HART
金额:
$32.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2018-05-31
关键词:
ATP HydrolysisAffectApoptosisBiological AssayCalciumCardiacCardiac MyocytesCardiac MyosinsCardiomyopathiesCardiovascular DiseasesCell NucleusCell physiologyCellsChronicContractile ProteinsCouplingCytoplasmDiabetes MellitusDissociationElectron TransportEnzymesEpidemicEventFunctional disorderGlucoseGlycoconjugatesHeart failureHyperglycemiaIndividualInstructionInsulin ResistanceKineticsLeadMapsMediatingMetabolicMethodsMicrofilamentsMitochondriaMitochondrial ProteinsModificationMolecularMyocardial InfarctionNutrientO-GlcNAc transferasePhosphorylationPhysiologicalPhysiologyPlayPost-Translational Protein ProcessingPrincipal InvestigatorProductionPropertyProtein IsoformsProteinsProteomeProteomicsRNA SplicingRattusReactive Oxygen SpeciesRegulationRisk FactorsRoleSiteStressTestingTherapeutic InterventionTimeToxic effectTroponinUDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferaseVariantWorkdiabeticdiabetic cardiomyopathydiabetic ratinorganic phosphatemitochondrial dysfunctionnovelprotein distributionresponsesugartandem mass spectrometrytool
中文摘要
instmctions):
英文摘要
instmctions):
Diabetes is a major risk factor for cardiovascular disease, culminating in myocardial infarction, and heart
failure. Prolonged hyper-0-GlcNAcylation, due to nutrient excess and hyperglycemia, is a major molecular
cause of glucose toxicity and insulin resistance. Increased 0-GlcNAcylation directly contributes to diabetic
cardiomyopathy and to dysfunctional mitochondria, perhaps contributing to excessive production of reactive
oxygen species (ROS). Even though 0-GlcNAcylation clearly plays an important role in diabetic
cardiovascular disease, virtually nothing is known about 0-GlcNAcylation in the cardiomyocyte. This project
will elucidate the roles of 0-GlcNAc in diabetic cardiomyopathy and will define the "0-GlcNAcome" of the
cardiomyocyte at the site-specific level. Specific Aims:
Aim 1: Quantify the Site-Specific Crosstalk Between 0-GlcNAcylation and Phosphorylation in the
cardiomyocyte proteome and in purified cardiomyocyte mitochondria from Normal and Diabetic
Rats. Using chemico-enzymatic photocleavable tag enrichment combined with electron transfer dissociation
(ETD) tandem mass spectrometry, we will quantify site occupancy for both 0-GlcNAc and phosphate in
cardiomyocyte contractile and mitochondrial proteins from normal and diabetic rats. Aim 2: Determine the
Specific Roles of 0-GlcNAcylation in normal cardiomyocyte mitochondria, and the sites of action
and mechanisms of diabetes-induced dysfunction, leading to ROS production. We wilt specifically alter
0-GlcNAcylation using methods developed during the past 20-years, and correlate alterations with specific
mitochondrial function. Aim 3: Elucidate the properties and regulation of cardiomyocyte mitochondrial
isoforms of O-GlcNAc Transferase and 0-GlcNAcase. Virtually nothing is known about the mitochondrial
isoforms of 0-GlcNAc Transferase (OGT) or 0-GlcNAcase (OGA). We will elucidate their localization,
activities, molecular associations and kinetic activities in mitochondria from normal and diabetic rats. Aim 4:
Evaluate the affects and roles of diabetes-induced mitochondrial dysfunction and increased O-
GlcNAcylation of cardiomyocyte contractile machinery on cardiac physiology and function. Working
closely with Core D we will systematically evaluate the importance of the crosstalk between 0-GlcNAcylation
and phosphorylation of cardiomyocyte contractile and mitochondrial proteins on the physiological functions of
cardiomyocytes
These studies will open a new paradigm for understanding the regulation of cardiac functions and in
diabetic cardiomyopathies. They will lead to totally unexplored avenues of possible therapeutic interventions
RELEVANCE (See instructions):
Diabetes is a major epidemic and contributes to cardiovascular disease, which ultimately results in
heart failure or myocardial infarction. Increased 0-GlcNAcylation, a sugar post-translational modification,
underlies molecular events contributing to diabetic cardiomyopathies by affecting the functions of contractile
and mitochondrial proteins within the cardiomyocyte. These studies will elucidate the importance of O-
GlcNAc in both normal and diabetic cardiomyocyte physiology, and will possibly lead to novel treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Translation by O-GlcNAc - Resubmission 03-05-2020
-
批准号:10308411
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2020
-
负责人:GERALD Warren HART
-
依托单位:
Regulation of Translation by O-GlcNAc - Resubmission 03-05-2020
-
批准号:10533317
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2020
-
负责人:GERALD Warren HART
-
依托单位:
Nutrient Regulation of Cell Physiology by O-GlcNAcylation
-
批准号:10458006
-
项目类别:
-
资助金额:$28.73万
-
财政年份:2016
-
负责人:GERALD Warren HART
-
依托单位:
Nutrient Regulation of Cell Physiology by O-GlcNAcylation
-
批准号:10261390
-
项目类别:
-
资助金额:$28.71万
-
财政年份:2016
-
负责人:GERALD Warren HART
-
依托单位:
Nutrient Regulation of Cell Physiology by O-GlcNAcylation
-
批准号:10668984
-
项目类别:
-
资助金额:$28.72万
-
财政年份:2016
-
负责人:GERALD Warren HART
-
依托单位:
Nutrient Regulation of Cell Physiology by O-GlcNAcylation
-
批准号:9329448
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2016
-
负责人:GERALD Warren HART
-
依托单位:
Nutrient Regulation of Cell Physiology by O-GlcNAcylation
-
批准号:9754184
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2016
-
负责人:GERALD Warren HART
-
依托单位:
"Glycosciences Skills Development "
-
批准号:8183699
-
项目类别:
-
资助金额:$5.71万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Administrative Core
-
批准号:8183684
-
项目类别:
-
资助金额:$10.65万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8669110
-
项目类别:
-
资助金额:$251.32万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8072358
-
项目类别:
-
资助金额:$243.63万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8289623
-
项目类别:
-
资助金额:$244.69万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:9067492
-
项目类别:
-
资助金额:$225.94万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8477248
-
项目类别:
-
资助金额:$236.62万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Shared Resource Cores
-
批准号:8183701
-
项目类别:
-
资助金额:$62.86万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8656256
-
项目类别:
-
资助金额:$5.18万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Glycoconjugates and Cardiovascular Disease
-
批准号:8853915
-
项目类别:
-
资助金额:$247.05万
-
财政年份:2011
-
负责人:GERALD Warren HART
-
依托单位:
Mechanisms of Glucose Toxicity
-
批准号:7762380
-
项目类别:
-
资助金额:$49.2万
-
财政年份:2010
-
负责人:GERALD Warren HART
-
依托单位:
O-GlcNAc:Developing New Tool for Assessment of Glycemia
-
批准号:7491662
-
项目类别:
-
资助金额:$46.01万
-
财政年份:2005
-
负责人:GERALD Warren HART
-
依托单位:
O-GlcNAc:Developing New Tool for Assessment of Glycemia
-
批准号:6928686
-
项目类别:
-
资助金额:$34.32万
-
财政年份:2005
-
负责人:GERALD Warren HART
-
依托单位:
海外基金